Salix Pharmaceuticals Newswire (Page 3)

Salix Pharmaceuticals Newswire (Page 3)

Comprehensive Real-Time News Feed for Salix Pharmaceuticals. (Page 3)

Results 41 - 60 of 1,736 in Salix Pharmaceuticals

  1. Valeant Pharmaceuticals Just Delivered a Trifecta of Bad News in Its Q3 ReportRead the original story w/Photo

    Nov 9, 2016 | The Motley Fool

    ... to rid itself of debt. Recent reports have suggested that Valeant could be in discussions to sell its Salix Pharmaceuticals operating segment to Japan's Takeda Pharmaceutical and another unnamed suitor for approximately $10 billion. According to ...

    Comment?

  2. Why Valeant Stock Is DownRead the original story w/Photo

    Nov 8, 2016 | Money Morning

    ... That was a 30% decline year over year (YOY) on lower product sales revenue from existing businesses. Salix Pharmaceuticals, which Valeant owns, kicked in $436 million in revenue in Q3. That was down from $461 million a year ago. Valeant's hefty loss ...

    Comment?

  3. Valeant Pharmaceuticals Reports Big Q3 Loss on Lower Product SalesRead the original story w/Photo

    Nov 8, 2016 | The Motley Fool

    ... charge of $1.05 billion. Valeant wrote off this large amount largely because the value of the Salix Pharmaceuticals business acquired in 2015 has deteriorated. Chairman and CEO Joseph Papa didn't talk much about the third-quarter results, choosing ...

    Comment?

  4. Valeant slashes outlook as revenue falls shortRead the original story w/Photo

    Nov 8, 2016 | MarketWatch

    ... to $471 million. Last week, The Wall Street Journal reported Valeant was in advanced talks to sell its Salix Pharmaceuticals Ltd. stomach-drug business to Japan's Takeda Pharmaceutical Co. for $10 billion and is exploring a sale of its eye-surgery ...

    Comment?

  5. Valeant Stock Slides After Profit Forecast Is ChoppedRead the original story w/Photo

    Nov 8, 2016 | Wall Street Journal

    ... Thomson Reuters. Last week, The Wall Street Journal reported Valeant was in advanced talks to sell its Salix Pharmaceuticals Ltd. stomach-drug business to Japan's Takeda Pharmaceutical Investors have been watching for signs of what kind of ...

    Comment?

  6. Atlantic Healthcare Granted U.S. Patent Extending IP Cover Of...Read the original story

    Nov 6, 2016 | BioSpace

    ... by LDC (the private equity division of Lloyd's Banking Group), with investment from founders of both Salix Pharmaceuticals and Clinigen Group, and existing shareholders. About Alicaforsen Alicaforsen enema has the potential to establish a new class ...

    Comment?

  7. RedHill Biopharma to Host Third Quarter 2016 Financial Results Conference Call on November 14, 2016Read the original story

    Nov 7, 2016 | P&T Community

    ... and an ongoing Phase II study for IBS-D; (iv) RHB-106 - an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; (v) YELIVAa (ABC294640) - a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting ...

    Comment?

  8. RedHill Biopharma to Present at the Jefferies 2016 London Healthcare ConferenceRead the original story

    Nov 7, 2016 | P&T Community

    ... and an ongoing Phase II study for IBS-D; (iv) RHB-106 - an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; (v) YELIVAa (ABC294640) - a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting ...

    Comment?

  9. Private Sector Jobs Increase, but at a Slower RateRead the original story

    Nov 3, 2016 | Morningstar

    ... get a better understanding of the economy's direction. Valeant Pharmaceuticals is in talks to sell its Salix Pharmaceuticals business for about $10 billion. The fact that it's trying to sell something it acquired less than two years ago suggests ...

    Comment?

  10. RedHill Biopharma Announces Withdrawal Of Public Offering Of Its American Depositary SharesRead the original story

    Nov 2, 2016 | BioSpace

    ... and an ongoing Phase II study for IBS-D; (iv) RHB-106 - an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; (v) YELIVA(TM) (ABC294640) - a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting ...

    Comment?

  11. Should Valeant Shareholders Be Content With The Firesale Beginning?Read the original story w/Photo

    Nov 3, 2016 | Seeking Alpha

    ... Salix for $10 billion will eliminate one of Valeant's most promising areas for potential growth. Salix Pharmaceuticals was a company devoted towards licensing drugs for gastrointestinal disorders. At the time of the acquisition, Salix was reporting ...

    Comment?

  12. Valeant, Pushing to Pare Debt, Weighs Sale of Eye-Surgery UnitRead the original story w/Photo

    Nov 2, 2016 | Wall Street Journal

    ... people said. The Wall Street Journal reported yesterday that Valeant is in advanced talks to sell its Salix Pharmaceuticals Ltd. stomach-drug business to Japan's Takeda Pharmaceutical for $10 billion, including $8.5 billion in cash and the rest in ...

    Comment?

  13. Negative Analyst Commentary Pushes Valeant Pharmaceuticals Intl. Inc. Lower by 11%Read the original story w/Photo

    Nov 2, 2016 | The Motley Fool

    The culprit appears to be unfavorable analyst chatter. As a quick refresher , The Wall Street Journal reported late yesterday afternoon that Valeant was in talks with Japan's Takeda Pharmaceutical and possibly another unnamed suitor to sell its Salix Pharmaceuticals franchise for about $10 billion.

    Comment?

  14. Valeant Pharmaceuticals News Hasn't Changed Our StanceRead the original story w/Photo

    Nov 2, 2016 | Money Morning

    ... billion in cash and future payments to Valeant. The two drug giants could reach a deal for Valeant's Salix Pharmaceuticals Ltd. unit in the coming weeks. That caused the Valeant Pharmaceuticals International Inc. (NYSE: VRX ) stock price to climb ...

    Comment?

  15. Biotech Forum Daily Digest: Can Biotech Rebound In November? Revisiting Redhill BiopharmaRead the original story w/Photo

    Nov 2, 2016 | Seeking Alpha

    ... Pharmaceuticals (NYSE: VRX ) is getting a huge bounce today as it is "shopping" its 2015 purchase of Salix Pharmaceuticals (NASDAQ: SLXP ) for some $10 billion. That is a far cry from the almost $15 billion it bought the firm for last year. However, ...

    Comment?

  16. Wall Street just raised an eyebrow at ValeantRead the original story w/Photo

    Nov 2, 2016 | Silicon Alley Insider

    The news that Valeant Pharmaceuticals is in talks to sell a core piece of its business, a unit called Salix Pharmaceuticals, has been met with a raised eyebrows all around Wall Street. Wells Fargo's David Maris described it as "selling the stove to keep the restaurant."

    Comment?

  17. Japan's Takeda Seeks to Expand OverseasRead the original story w/Photo

    Nov 1, 2016 | Wall Street Journal

    ... and other areas. People familiar with the matter said Takeda could reach a deal with Valeant for Salix Pharmaceuticals Ltd., which Valeant bought a year and a half ago . The deal size could be about $10 billion, including $8.5 billion in cash and ...

    Comment?

  18. Valeant in Talks to Sell Stomach-Drug BusinessRead the original story w/Photo

    Nov 1, 2016 | Wall Street Journal

    The companies could reach a deal for Salix Pharmaceuticals Ltd., which Valeant bought just a year-and-a-half ago for roughly $11 billion, in the coming weeks, people familiar with the matter said. The purchase price would include about $8.5 billion in cash and future royalty payments to Valeant, the people said.

    Comment?

  19. CommentsRead the original story w/Photo

    Nov 1, 2016 | Wall Street Journal

    ... The companies could reach a deal for Salix Pharmaceuticals Ltd., which Valeant bought just a year-and-a-half ago for roughly $11 billion, in the coming weeks, people familiar with the matter said. The purchase price would include about $8.5 billion ...

    Comment?

  20. Wednesday newspaper round-up: Hammond, disposable incomes, HeathrowRead the original story w/Photo

    Feb 11, 2016 | Live Charts

    ... Times Takeda, Japan's largest pharmaceutical group, is in advanced talks with Valeant to acquire Salix Pharmaceuticals for about $10bn, according to people briefed about the negotiations. The exact terms of the potential transaction for the ...

    Comment?